Modeling and correction of structural variations in patient-derived iPSCs using CRISPR/Cas9

Nat Protoc. 2016 Nov;11(11):2154-2169. doi: 10.1038/nprot.2016.129. Epub 2016 Oct 6.

Abstract

Genome engineering technology using engineered nucleases has been rapidly developing, enabling the efficient correction of simple mutations. However, the precise correction of structural variations (SVs) such as large inversions remains limited. Here we describe a detailed procedure for the modeling or correction of large chromosomal rearrangements and short nucleotide repeat expansions using engineered nucleases in human induced pluripotent stem cells (hiPSCs) from a healthy donor and patients with SVs. This protocol includes the delivery of engineered nucleases with no donor template to hiPSCs, and genotyping and derivation/characterization of gene-manipulated hiPSC clones. With engineered nucleases, genomic inversions, reversions, and deletions of short nucleotide expansions can be identified in 2 weeks, and desired clones can be generated in as little as 3-4 weeks. This protocol enables the correction of large inverted segments and short nucleotide repeat expansions in diseases such as hemophilia A, fragile X syndrome, Hunter syndrome, and Friedreich's ataxia.

MeSH terms

  • Base Sequence
  • CRISPR-Cas Systems / genetics*
  • DNA End-Joining Repair / genetics
  • Gene Rearrangement / genetics
  • Genetic Engineering / methods*
  • Genetic Variation*
  • Genome, Human / genetics
  • Humans
  • Induced Pluripotent Stem Cells / metabolism*
  • Models, Genetic*
  • Repetitive Sequences, Nucleic Acid / genetics